FDA accepts Lumicell breast cancer optical imaging agent NDA

By AuntMinnie.com staff writers

May 22, 2023 -- The U.S. Food and Drug Administration (FDA) has accepted for review Lumicell's new drug application for its Lumisight optical imaging agent for breast cancer and a premarket approval application for the company's direct visualization system.

Lumisight and Lumicell Direct Visualization help clinicians assess the lumpectomy cavity of the breast, according to Lumicell. The company's direct visualization system consists of a handheld imaging probe that can be inserted into the breast cavity and cancer detection software to identify residual disease.

The applications are supported by data from more than 700 breast cancer patients; clinical results regarding the performance of Lumisight and Lumicell DVS have been published in NEJM Evidence and JAMA Surgery.


Copyright © 2023 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
What's this?
Sign in using your social networking
account:
(What's this?)


Forgot your password?
|
View our privacy policy.